KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Astrazeneca (AZN) Raw Materials (2016 - 2025)

Astrazeneca (AZN) has 3 years of Raw Materials data on record, last reported at $1.9 billion in Q4 2025.

  • For Q4 2025, Raw Materials rose 24.71% year-over-year to $1.9 billion; the TTM value through Dec 2025 reached $1.9 billion, up 24.71%, while the annual FY2025 figure was $1.9 billion, 24.71% up from the prior year.
  • Raw Materials reached $1.9 billion in Q4 2025 per AZN's latest filing, up from $1.5 billion in the prior quarter.
  • Across five years, Raw Materials topped out at $1.9 billion in Q4 2025 and bottomed at $1.5 billion in Q4 2024.
  • Average Raw Materials over 3 years is $1.6 billion, with a median of $1.5 billion recorded in 2023.
  • Peak YoY movement for Raw Materials: dropped 2.74% in 2024, then rose 24.71% in 2025.
  • A 3-year view of Raw Materials shows it stood at $1.5 billion in 2023, then dropped by 2.74% to $1.5 billion in 2024, then increased by 24.71% to $1.9 billion in 2025.
  • Per Business Quant database, its latest 3 readings for Raw Materials were $1.9 billion in Q4 2025, $1.5 billion in Q4 2024, and $1.5 billion in Q4 2023.